Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 1.2% 8.40 8.20 8.40 8.40 8.30 8.30 399,964 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 23

Evgen Pharma PLC Result of Open Offer

03/03/2021 7:00am

UK Regulatory (RNS & others)


Evgen Pharma (LSE:EVG)
Historical Stock Chart


From Feb 2021 to Apr 2021

Click Here for more Evgen Pharma Charts.

TIDMEVG

RNS Number : 9327Q

Evgen Pharma PLC

03 March 2021

THIS ANNOUNCEMENT AND THE INFORMATION IN IT, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION OF THAT JURISDICTION. THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU) NO 596/2014, AS AMENDED. UPON PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

TERMS NOT OTHERWISE DEFINED HEREIN SHALL HAVE THE MEANINGS GIVEN TO THEM IN THE COMPANY'S CIRCULAR DATED 12 FEBRUARY 2021.

For immediate release

3 March 2021

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Result of Open Offer

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, is pleased to announce the results of its Open Offer.

On 2 February 2021, Evgen announced its intention to raise gross proceeds of up to GBP11 million by way of a Placing and Open Offer, all at an issue price of 8 pence per New Ordinary Share. A total of 137,490,676 New Ordinary Shares will be issued at the Issue Price (subject to the conditions noted below), of which, 12,490,676 New Ordinary Shares will be issued pursuant to the Open Offer. This brings the gross proceeds of the Fundraising to approximately GBP11 million before expenses.

The Open Offer closed for acceptances at 11.00 a.m. yesterday. The Company has received valid acceptances from Qualifying Shareholders in respect of their Basic Entitlements in respect of 5,389,931 New Ordinary Shares, representing approximately 43 per cent. of the Open Offer Shares. In addition, the Company has received applications from Qualifying Shareholders under the Excess Application Facility in respect of 14,359,431 New Ordinary Shares, representing a total over-subscription of approximately 58 per cent. of the available Open Offer Shares. Accordingly, Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full Basic Entitlements. As applications under the Excess Application Facility cannot be satisfied in full, applications for New Ordinary Shares under the Excess Application Facility will be scaled back in accordance with the terms set out in the Circular.

General Meeting

The Fundraising remains conditional on the approval by Shareholders of the Resolutions at the Company's General Meeting to be held at 10:00 a.m. today (or any adjournment thereof), the satisfaction of certain conditions in the Placing Agreement and Admission of the New Ordinary Shares to trading on AIM occurring at or before 8.00 a.m. on 4 March 2021 (or such later date as the Company and finnCap may agree, being not later than 8.00 a.m. on 18 March 2021).

The Company will announce the results of the General Meeting as soon as practicable after the meeting concludes.

Enquiries:

 
 Evgen Pharma plc                                                         Via Walbrook 
  Barry Clare, Chairman 
  Dr Huw Jones, CEO 
  Richard Moulson, CFO 
 finnCap 
  Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
  Alice Lane / Sunila de Silva 
  (ECM) 
  www.finncap.com                                                 +44 (0) 20 7220 0500 
 Walbrook PR                              +44 (0)20 7933 87870 or evgen@walbrookpr.com 
  Paul McManus/ Anna Dunphy                          +44 (0)7980 541 893 / +44 (0)7876 
                                                                               741 001 
 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROIBCGDXDBGDGBD

(END) Dow Jones Newswires

March 03, 2021 02:00 ET (07:00 GMT)

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210414 22:04:04